This notice has been superseded. See the latest notice: Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (Solicitation)
SolicitationActiveHT9427-26-R-E020
Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination
DEPT OF DEFENSE / DEFENSE HEALTH AGENCY (DHA) / DEFENSE HEALTH AGENCYKey dates?
- Posted?
- Sep 23, 2026
- Response deadline?
- Oct 23, 2026, 4:00 PM UTC
- Archive date?
- Nov 7, 2026
- Archive type?
- auto15
Classification?
- Notice type?
- Solicitation
- Base type?
- Solicitation
- Set-aside?
- —
- Set-aside code?
- —
- PSC?
- AN13
NAICS?
Issuing office?
- Department?
- DEPT OF DEFENSE
- Sub-tier?
- DEFENSE HEALTH AGENCY (DHA)
- Office?
- DEFENSE HEALTH AGENCY
- Office code?
- 097.97DH.HT9427
- Organization type?
- OFFICE
- Office address?
- FORT DETRICK, MD, 21702, USA
Place of performance?
- Street?
- —
- Street 2?
- —
- City?
- Frederick
- State?
- Maryland
- Zip?
- —
- Country?
- UNITED STATES
Contacts?
- Julie Burnsprimary
- Bryan Heickmansecondary
Description?
This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections. This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product. The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance). The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022.
Attachments (14)?
- Download📎 Attachment+I1+-+Technology+Readiness+Level+%28TRL%29+for+drug+and+biologics+%28REFERENCE+ONLY%29.pdfapplication/pdf · 241 KB
- Download📎 Attachment+I2-Technology+Readiness+Level+%28TRL%29+for+diagnostics+and+devices+%28REFERENCE+ONLY%29.pdfapplication/pdf · 269 KB
- Download📎 HT9427-26-R-E020-RPP+for+BWI-PT-Barrier+%28pOTA%29.pdfapplication/pdf · 379 KB
- Download📎 Attachment+D2+-+FDA+Form+1571+Instructions+%28REFERENCE+ONLY%29.pdfapplication/pdf · 342 KB
- Download📎 Attachment+G2+-+Firm+Fixed+Price+Sheet+Template.xlsxapplication/octet-stream · 143 KB
- Download📎 Attachment+J+-+Offeror+question+form.xlsxapplication/octet-stream · 11 KB
- Download📎 Attachment+D1+-+FDA+Form+1571.pdfapplication/pdf · 388 KB
- Download📎 Attachment+B+-+Contract+Data+Requirements+List+%28CDRL%29.pdfapplication/pdf · 54 KB
- Download📎 Attachment+A+-+Statement+of+Objectives+%28SOO%29.pdfapplication/pdf · 189 KB
- Download📎 Attachment+F+-+Warranties+and+Representatives.docxapplication/octet-stream · 30 KB
- Download📎 Attachment+C+-+Data+Item+Description+%28DID%29+DI-TCSP-82040+%28REFERENCE+ONLY%29.pdfapplication/pdf · 353 KB
- Download📎 Attachment+E+-+Draft+Agreement+Terms+and+Conditions.pdfapplication/pdf · 781 KB
- Download📎 Attachment+G1+-+Cost+Sheet+Template.xlsxapplication/octet-stream · 158 KB
- Download📎 Attachment+H+-+Statement+of+Work+Template+%28see+Section+11%29.docxapplication/octet-stream · 61 KB
Other notices in this solicitation?
Similar open contracts
Metadata?
- Notice ID?
- 93963f59cd0a4b8eb1faa2e99cc77c36
- Full path?
- DEPT OF DEFENSE.DEFENSE HEALTH AGENCY (DHA).DEFENSE HEALTH AGENCY
- Office code?
- 097.97DH.HT9427
- Ingested?
- Sep 24, 2026
- Updated?
- Sep 29, 2026